Speakers

HomeSpeakers ▶ Onsite Disclosure of Commercial Support and Relevant Financial Interests
Onsite Disclosure of Commercial Support and Relevant Financial Interests

Posters must briefly acknowledge: any commercial support of the original research presented; any financial interests held by the first, last, and corresponding author of the research presented, and the poster presenter if different, in a commercial entity that is relevant to the subject matter of the original research presented, within the past 12 months.

  • This disclosure statement is commonly positioned in a box in the lower right of the poster.
  • For poster disclosures the ATS defines commercial support as: any funding or in-kind support provided by a commercial entity to the authors noted above, or their institutions, in direct support of the original research presented. (Support provided by providers of clinical service directly to patients, such as authors’ institutions, is not regarded as commercial support and does not require disclosure.)
  • For poster disclosures the ATS defines relevant financial interests as including: 1) Any compensable services provided by the authors noted above to a commercial entity that has business interests relevant to the original research presented, such as a pharmaceutical company or medical device company, product manufacturer, investment firm, or law firm representing a relevant commercial entity, even if uncompensated. Examples of common industry-compensated types of relationships are consulting, advisory committees, speaking, expert testimony commissioned by a relevant company or its agents, travel support, and in-kind provision of equipment or services. (2) Any equity interests in an entity relevant to the original research presented, including stock, stock options, or other ownership interest, excluding general mutual funds; (3) Any intellectual property rights held directly by an author that are relevant to the subject matter of the original research presented, such as a patent, whether granted or pending, or a copyright.
  • Poster disclosures should consist of the author’s name followed by the name of the company involved and the type of relationship involved (examples above). Disclosures should not use company logos or brand or proprietary drug or device names.